Alchemab Is Bringing A New Meaning To Patient-Centered Care

British-Bostonian Biotech Is Working Backwards To Explain Disease Resilience

Alchemab Therapeutics sequences the antibodies of patients who prove especially resilient to hard-to-treat diseases to try and find therapeutic targets.

Depiction of an antibody
Alchemab is sequencing patients' B-cells in the hope of finding treatments for serious illnesses • Source: Shutterstock

At Alchemab Therapeutics the first step in the drug discovery journey starts not in a laboratory but with an individual person – not a scientist or researcher, but a patient. The biotech aims to target diseases across neurology and oncology through naturally occurring protective antibodies, mining the antibody receptors of individuals who are especially resistant to or have even recovered from serious illness to develop therapeutic products.

More from Innovation

Innovation And Accessibility: India’s Advanced Therapy Pricing Challenge

 
• By 

As India prepares to commercialize its first advanced therapies it must engage key stakeholders to ensure successful implementation. Learning from global best practices and managing pricing strategies will be crucial to maximize access, deliver high-quality outcomes, and sustain innovation through reinvestment in R&D.

The Scottish Biotech Harnessing The Power Of VLPs For Chronic Immune Conditions

 
• By 

Glen Clova Scientific is galvanizing virus-like particle technology with disruptive advances in manufacturing to treat immune-related dermatology conditions in often overlooked senile populations.

Podcast: The Future Of Immunotherapy

 
• By 

In this episode of the In Vivo podcast, Harvard immunologist and co-founder of early-stage biotech Corner Therapeutics, Jonathan Kagan, talks about harnessing the power of the innate immune system by weaponizing dendritic cells and creating immunotherapies that are safer and more durable.

Alternatives to Animal Testing: A Tech Run-Down

 
• By 

New alternative methods to animal testing in early drug development are increasing in sophistication and predictability, yet they are vastly underutilized. In Vivo presents an overview of select technologies and vendors.

More from In Vivo

Finding The Balance: First-In-Class Versus Best-In-Class

 
• By 

As pharmaceutical companies face a crowded and competitive landscape, the debate between being first-in-class or best-in-class is evergreen. This strategic choice impacts new product launches, with first-to-market therapies offering market share and brand recognition advantages, while best-in-class options can capture value through product differentiation and commercial execution. In Vivo talked to L.E.K. Consulting on how to make a product stand out from the crowd.

Pharma’s Future: Key Therapeutic Areas Set For Major Growth

 

As the pharmaceutical sector evolves, the landscape of sales-driving indications is set for transformation by 2030. This article explores the therapeutic areas poised for substantial growth and examines how leading companies are strategically positioning themselves to capitalize on these emerging opportunities.

Alternatives to Animal Testing: A Tech Run-Down

 
• By 

New alternative methods to animal testing in early drug development are increasing in sophistication and predictability, yet they are vastly underutilized. In Vivo presents an overview of select technologies and vendors.